Takeda Pharmaceutical's sales revenue of products FY 2022
In the 2022 fiscal year, the leading product in terms of sales of the Japanese pharmaceutical company Takeda Pharmaceutical Co., Ltd. was Entyvio, with a sales value of more than 702 billion Japanese yen. Entyvio is a prescription drug treating adult patients with ulcerative colitis and Crohn's disease.